首页 > 最新文献

Infection and Chemotherapy最新文献

英文 中文
The Story and Implications of the Korean Health Care Facility Counseling Project on People Living with HIV. 韩国卫生保健机构艾滋病毒感染者咨询项目的故事和影响。
IF 4.2 Q2 INFECTIOUS DISEASES Pub Date : 2023-06-01 DOI: 10.3947/ic.2023.0024
Jae-Phil Choi, JungHui Lee, Jong Mi An, Jihyun Kim, Nari Won, Young Hwa Choi

In 2005, the Korea Disease Control and Prevention Agency (KDCA) launched "Health Care Facility Counseling Project on People Living with human immunodeficiency virus (HIV)" funded by the private-subsidy project for the prevention of acquired immune deficiency syndrome (AIDS) and sexually transmitted diseases to provide people living with HIV (PLWH) psychological support and counsel them about the disease and antiretroviral therapy (ART). Currently, 38 counseling nurse specialists work at 28 healthcare facilities for patient care. Of all PLWH in Korea, 71.9% received benefits from the Counseling Project. Adherence to ART medication (>95.0%), level of depression or anxiety, counseling coverage, and viral load status were monitored as common project indicators. Various specialized programs have been implemented in diverse facilities. This project has played a pivotal role in HIV care continuum and viral suppression policies, resulting in 95.9% of PLWH maintaining undetectable status (<40 copies/ml) in 2021. In this review, we present the chronology and fulfillment of this project, which will be an essential step for future planning in the context of aging and the chronic comorbid nature of HIV/AIDS.

2005年,韩国疾病防治署启动了"保健设施艾滋病毒感染者咨询项目",该项目由预防获得性免疫缺陷综合症(艾滋病)和性传播疾病私人补贴项目资助,目的是向艾滋病毒感染者提供心理支持,并就该疾病和抗逆转录病毒疗法向他们提供咨询。目前,有38名咨询护士专家在28家医疗机构为患者提供护理。在韩国所有的PLWH中,71.9%的人从咨询项目中受益。ART药物依从性(>95.0%)、抑郁或焦虑水平、咨询覆盖率和病毒载量状态作为共同项目指标进行监测。在不同的设施中实施了各种专业方案。该项目在艾滋病毒护理连续性和病毒抑制政策方面发挥了关键作用,导致95.9%的艾滋病毒感染者仍处于未检测状态(
{"title":"The Story and Implications of the Korean Health Care Facility Counseling Project on People Living with HIV.","authors":"Jae-Phil Choi,&nbsp;JungHui Lee,&nbsp;Jong Mi An,&nbsp;Jihyun Kim,&nbsp;Nari Won,&nbsp;Young Hwa Choi","doi":"10.3947/ic.2023.0024","DOIUrl":"https://doi.org/10.3947/ic.2023.0024","url":null,"abstract":"<p><p>In 2005, the Korea Disease Control and Prevention Agency (KDCA) launched \"Health Care Facility Counseling Project on People Living with human immunodeficiency virus (HIV)\" funded by the private-subsidy project for the prevention of acquired immune deficiency syndrome (AIDS) and sexually transmitted diseases to provide people living with HIV (PLWH) psychological support and counsel them about the disease and antiretroviral therapy (ART). Currently, 38 counseling nurse specialists work at 28 healthcare facilities for patient care. Of all PLWH in Korea, 71.9% received benefits from the Counseling Project. Adherence to ART medication (>95.0%), level of depression or anxiety, counseling coverage, and viral load status were monitored as common project indicators. Various specialized programs have been implemented in diverse facilities. This project has played a pivotal role in HIV care continuum and viral suppression policies, resulting in 95.9% of PLWH maintaining undetectable status (<40 copies/ml) in 2021. In this review, we present the chronology and fulfillment of this project, which will be an essential step for future planning in the context of aging and the chronic comorbid nature of HIV/AIDS.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"55 2","pages":"167-178"},"PeriodicalIF":4.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/56/df/ic-55-167.PMC10323534.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9795329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mycobacterium intracellulare Tenosynovitis with Rice Body Formation with Literature Review. 分枝杆菌胞内腱鞘炎伴水稻体形成并文献综述。
IF 4.2 Q2 INFECTIOUS DISEASES Pub Date : 2023-06-01 DOI: 10.3947/ic.2022.0025
Cheon Hoo Jeon, Tae Woo Kim, Joon Young Park, Chung Su Hwang, Seungjin Lim

Rice body formation is a rare response to chronic inflammation of the synovial membrane. It is most commonly associated with rheumatoid arthritis and tuberculosis. Recently, there have been reports of rice bodies caused by non-tuberculous mycobacterial infection. We describe a case of rice body formation in a 69-year-old man who presented with pain and swelling in his third finger for six months after being punctured by a wire 1 year ago. He had no other notable recent medical history. Magnetic resonance imaging showed a large amount of fluid collection with diffuse thickening and enhancement of the synovium and rice bodies along the flexor tendon of the third finger. During surgery, multiple granular white rice bodies were found from the third carpal bone to the distal phalanx. Mycobacterium intracellulare was identified through mycobacterial culture and the patient was treated with rifampin, ethambutol, and clarithromycin, without recurrence. This case reveals that Mycobacterium intracellulare infection can cause tenosynovitis with rice bodies.

米体形成是对滑膜慢性炎症的罕见反应。它最常与类风湿关节炎和肺结核有关。最近,有非结核分枝杆菌感染引起水稻体的报道。我们描述了一个69岁男性的大米体形成病例,他在1年前被金属丝刺穿后,表现为第三指疼痛和肿胀6个月。他最近没有其他明显的病史。磁共振成像显示大量积液伴弥漫性增厚,滑膜和米体沿第三指屈肌腱增强。手术中,从第三腕骨到远端指骨发现多个颗粒状白米体。通过分枝杆菌培养鉴定胞内分枝杆菌,患者给予利福平、乙胺丁醇和克拉霉素治疗,未复发。本病例提示胞内分枝杆菌感染可引起水稻体腱鞘炎。
{"title":"<i>Mycobacterium intracellulare</i> Tenosynovitis with Rice Body Formation with Literature Review.","authors":"Cheon Hoo Jeon,&nbsp;Tae Woo Kim,&nbsp;Joon Young Park,&nbsp;Chung Su Hwang,&nbsp;Seungjin Lim","doi":"10.3947/ic.2022.0025","DOIUrl":"https://doi.org/10.3947/ic.2022.0025","url":null,"abstract":"<p><p>Rice body formation is a rare response to chronic inflammation of the synovial membrane. It is most commonly associated with rheumatoid arthritis and tuberculosis. Recently, there have been reports of rice bodies caused by non-tuberculous mycobacterial infection. We describe a case of rice body formation in a 69-year-old man who presented with pain and swelling in his third finger for six months after being punctured by a wire 1 year ago. He had no other notable recent medical history. Magnetic resonance imaging showed a large amount of fluid collection with diffuse thickening and enhancement of the synovium and rice bodies along the flexor tendon of the third finger. During surgery, multiple granular white rice bodies were found from the third carpal bone to the distal phalanx. <i>Mycobacterium intracellulare</i> was identified through mycobacterial culture and the patient was treated with rifampin, ethambutol, and clarithromycin, without recurrence. This case reveals that <i>Mycobacterium intracellulare</i> infection can cause tenosynovitis with rice bodies.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"55 2","pages":"299-305"},"PeriodicalIF":4.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/0c/e3/ic-55-299.PMC10323524.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9841005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
HIV Service Delivery Innovations in the Philippines during the COVID-19 Pandemic. 新冠肺炎大流行期间菲律宾的艾滋病毒服务提供创新。
IF 2.8 Q2 INFECTIOUS DISEASES Pub Date : 2023-06-01 Epub Date: 2023-05-04 DOI: 10.3947/ic.2023.0025
Rowalt Alibudbud
{"title":"HIV Service Delivery Innovations in the Philippines during the COVID-19 Pandemic.","authors":"Rowalt Alibudbud","doi":"10.3947/ic.2023.0025","DOIUrl":"10.3947/ic.2023.0025","url":null,"abstract":"","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"55 2","pages":"283-284"},"PeriodicalIF":2.8,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/34/e9/ic-55-283.PMC10323522.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9786516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Incidence and Risk Factors of Tenofovir Disoproxil Fumarate Induced Nephrotoxicity and Renal Function Recovery, a Hospital Case-Control Study. 富马酸替诺福韦二氧吡酯肾毒性和肾功能恢复的发生率及危险因素:一项医院病例-对照研究
IF 4.2 Q2 INFECTIOUS DISEASES Pub Date : 2023-06-01 DOI: 10.3947/ic.2023.0001
Sirikan Srisopa, Akarawat Kornjirakasemsan, Pornpit Treebupachatsakul, Paveena Sonthisombat

Background: The incidence of tenofovir disoproxil fumarate (TDF)-induced nephrotoxicity ranges from 15.8 to 19.3 percent. Following cessation of TDF, approximately one-half of patients with nephrotoxicity regained full renal functions. This study aimed to determine the incidence and risk factors for nephrotoxicity, as well as the complete recovery of renal function, in human immunodeficiency virus (HIV)-infected patients receiving TDF regimens.

Materials and methods: This was a retrospective case-control study of HIV-positive patients who received TDF regimens from 2 tertiary hospitals between 2012 and 2018. Signs of TDF-induced renal dysfunction, defined as having estimated glomerular filtration rate (eGFR) decline of greater than 25%, and proximal renal tubulopathy (PRT) were followed for 48 months. After discontinuing TDF due to nephrotoxicity, the renal parameters of patients were monitored for 48 months. Univariate and multivariate regression analyses were used to determine the factors associated with TDF-induced nephrotoxicity and renal function recovery.

Results: Twelve percent of 3,214 TDF-treated patients were diagnosed with renal dysfunction, whereas 303 patients (15.20%) were diagnosed with PRT. TDF-induced renal dysfunction was associated with older age (odds ratio [OR] = 2.851), smoking (OR = 1.972), and TDF use for more than 3 years (OR 1.928). Receiving trimethoprim-sulfamethoxazole (TMP/SMX) or nonsteroidal anti-inflammatory drugs (NSAIDs) and being elderly were associated with PRT (OR = 4.727, 4.313, and 3.357, respectively). Following the discontinuation of TDF, 12.96% of patients regained full renal function. Elderly patients and those taking renin-angiotensin-aldosterone system (RAAS) inhibitors or protease inhibitors (PIs) had a lower likelihood of full recovery (OR = 0.811, 0.793, 0.582, respectively). One-third experienced PRT recovery, whereas RAAS inhibitors use, old age, and receiving PIs decreased the likelihood of PRT recovery (OR = 0.709, 0.504, 0.311, respectively). TDF cessation at an eGFR greater than 60 mL/min/1.73 m² increased the likelihood of renal function recovery and PRT by 4.07 and 2.11 times, respectively.

Conclusion: Twelve percent and 15 percent of patients receiving TDF developed renal dysfunction and PRT, respectively. Age, TMP/SMX, NSAIDs, and long-term TDF exposure were independent risk factors for TDF-induced nephrotoxicity. Thirteen and thirty-three percent of patients with renal dysfunction and PRT recovered from their conditions, respectively. The discontinuation of TDF at an eGFR greater than 60 mL/min/1.73 m² was advantageous for the recovery of renal function and PRT.

背景:富马酸替诺福韦二氧吡酯(TDF)引起的肾毒性发生率为15.8%至19.3%。停止TDF后,大约一半的肾毒性患者恢复了完全的肾功能。本研究旨在确定接受TDF方案的人类免疫缺陷病毒(HIV)感染患者肾毒性的发生率和危险因素,以及肾功能的完全恢复。材料和方法:本研究是一项回顾性病例对照研究,研究对象是2012年至2018年在2家三级医院接受TDF治疗的hiv阳性患者。tdf引起的肾功能障碍的症状,定义为肾小球滤过率(eGFR)下降超过25%,近端肾小管病变(PRT)随访48个月。在因肾毒性停用TDF后,对患者的肾脏参数进行48个月的监测。采用单因素和多因素回归分析确定与tdf引起的肾毒性和肾功能恢复相关的因素。结果:3214例tdf治疗的患者中有12%被诊断为肾功能不全,而303例(15.20%)被诊断为PRT。TDF引起的肾功能障碍与年龄较大(优势比[OR] = 2.851)、吸烟(OR = 1.972)和使用TDF超过3年(OR = 1.928)相关。服用甲氧苄啶-磺胺甲恶唑(TMP/SMX)或非甾体抗炎药(NSAIDs)且年龄较大与PRT相关(or分别为4.727、4.313和3.357)。停用TDF后,12.96%的患者恢复了完全的肾功能。老年患者与服用肾素-血管紧张素-醛固酮系统(RAAS)抑制剂或蛋白酶抑制剂(pi)的患者完全康复的可能性较低(or分别为0.811、0.793、0.582)。三分之一的患者PRT恢复,而使用RAAS抑制剂、年龄和接受pi降低了PRT恢复的可能性(OR分别为0.709、0.504和0.311)。在eGFR大于60 mL/min/1.73 m²时停止TDF,使肾功能恢复和PRT的可能性分别增加4.07倍和2.11倍。结论:接受TDF治疗的患者分别有12%和15%出现肾功能不全和PRT。年龄、TMP/SMX、非甾体抗炎药和长期TDF暴露是TDF引起肾毒性的独立危险因素。分别有13%和33%的肾功能不全和PRT患者从他们的病情中恢复过来。eGFR大于60 mL/min/1.73 m²时停用TDF有利于肾功能和PRT的恢复。
{"title":"Incidence and Risk Factors of Tenofovir Disoproxil Fumarate Induced Nephrotoxicity and Renal Function Recovery, a Hospital Case-Control Study.","authors":"Sirikan Srisopa,&nbsp;Akarawat Kornjirakasemsan,&nbsp;Pornpit Treebupachatsakul,&nbsp;Paveena Sonthisombat","doi":"10.3947/ic.2023.0001","DOIUrl":"https://doi.org/10.3947/ic.2023.0001","url":null,"abstract":"<p><strong>Background: </strong>The incidence of tenofovir disoproxil fumarate (TDF)-induced nephrotoxicity ranges from 15.8 to 19.3 percent. Following cessation of TDF, approximately one-half of patients with nephrotoxicity regained full renal functions. This study aimed to determine the incidence and risk factors for nephrotoxicity, as well as the complete recovery of renal function, in human immunodeficiency virus (HIV)-infected patients receiving TDF regimens.</p><p><strong>Materials and methods: </strong>This was a retrospective case-control study of HIV-positive patients who received TDF regimens from 2 tertiary hospitals between 2012 and 2018. Signs of TDF-induced renal dysfunction, defined as having estimated glomerular filtration rate (eGFR) decline of greater than 25%, and proximal renal tubulopathy (PRT) were followed for 48 months. After discontinuing TDF due to nephrotoxicity, the renal parameters of patients were monitored for 48 months. Univariate and multivariate regression analyses were used to determine the factors associated with TDF-induced nephrotoxicity and renal function recovery.</p><p><strong>Results: </strong>Twelve percent of 3,214 TDF-treated patients were diagnosed with renal dysfunction, whereas 303 patients (15.20%) were diagnosed with PRT. TDF-induced renal dysfunction was associated with older age (odds ratio [OR] = 2.851), smoking (OR = 1.972), and TDF use for more than 3 years (OR 1.928). Receiving trimethoprim-sulfamethoxazole (TMP/SMX) or nonsteroidal anti-inflammatory drugs (NSAIDs) and being elderly were associated with PRT (OR = 4.727, 4.313, and 3.357, respectively). Following the discontinuation of TDF, 12.96% of patients regained full renal function. Elderly patients and those taking renin-angiotensin-aldosterone system (RAAS) inhibitors or protease inhibitors (PIs) had a lower likelihood of full recovery (OR = 0.811, 0.793, 0.582, respectively). One-third experienced PRT recovery, whereas RAAS inhibitors use, old age, and receiving PIs decreased the likelihood of PRT recovery (OR = 0.709, 0.504, 0.311, respectively). TDF cessation at an eGFR greater than 60 mL/min/1.73 m² increased the likelihood of renal function recovery and PRT by 4.07 and 2.11 times, respectively.</p><p><strong>Conclusion: </strong>Twelve percent and 15 percent of patients receiving TDF developed renal dysfunction and PRT, respectively. Age, TMP/SMX, NSAIDs, and long-term TDF exposure were independent risk factors for TDF-induced nephrotoxicity. Thirteen and thirty-three percent of patients with renal dysfunction and PRT recovered from their conditions, respectively. The discontinuation of TDF at an eGFR greater than 60 mL/min/1.73 m² was advantageous for the recovery of renal function and PRT.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"55 2","pages":"226-236"},"PeriodicalIF":4.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/65/de/ic-55-226.PMC10323539.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9786515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Phenotypic Characteristics and Clonal Relationships of Stenotrophomonas maltophilia Isolates in Hospitalized Adults from a Private Center in Lima, Peru. 秘鲁利马一家私立中心住院成人嗜麦芽窄养单胞菌分离株的表型特征和克隆关系
IF 4.2 Q2 INFECTIOUS DISEASES Pub Date : 2023-06-01 DOI: 10.3947/ic.2023.0003
Tamin Ortiz-Gómez, Paula Toledano, Andrea C Gomez, María López, Carla Andrea Alonso, Joaquim Ruiz, José Lagos, Yolanda Sáenz

Stenotrophomonas maltophilia is an opportunistic pathogen, often associated with nosocomial infections. Ten S. maltophilia were isolated from clinical samples during the period January 2021 and June 2022. Eight (80%) patients had cancer as a background disease and 2 patients had coronavirus disease 2019. A fatal outcome was recorded in 4 cases (40% of patients). All the isolates were susceptible to minocycline and levofloxacin. Trimethoprim/sulfamethoxazole and ceftazidime resistance rates were 20% and 40% respectively. Eight different patterns were observed by Pulsed-Field Gel Electrophoresis, only two isolates being clonally identical. The isolation of S. maltophilia in clinical settings requires the implementation of infection prevention measures.

嗜麦芽窄养单胞菌是一种机会性病原体,常与医院感染有关。在2021年1月至2022年6月期间,从临床样本中分离到10株嗜麦芽链球菌。8例(80%)患者的背景疾病是癌症,2例患者患有2019冠状病毒病。有4例(40%的患者)发生死亡。所有菌株对米诺环素和左氧氟沙星均敏感。甲氧苄啶/磺胺甲恶唑耐药率为20%,头孢他啶耐药率为40%。通过脉冲场凝胶电泳检测到8种不同的模式,只有2株克隆相同。临床环境中嗜麦芽链球菌的分离需要实施感染预防措施。
{"title":"Phenotypic Characteristics and Clonal Relationships of <i>Stenotrophomonas maltophilia</i> Isolates in Hospitalized Adults from a Private Center in Lima, Peru.","authors":"Tamin Ortiz-Gómez,&nbsp;Paula Toledano,&nbsp;Andrea C Gomez,&nbsp;María López,&nbsp;Carla Andrea Alonso,&nbsp;Joaquim Ruiz,&nbsp;José Lagos,&nbsp;Yolanda Sáenz","doi":"10.3947/ic.2023.0003","DOIUrl":"https://doi.org/10.3947/ic.2023.0003","url":null,"abstract":"<p><p><i>Stenotrophomonas maltophilia</i> is an opportunistic pathogen, often associated with nosocomial infections. Ten <i>S. maltophilia</i> were isolated from clinical samples during the period January 2021 and June 2022. Eight (80%) patients had cancer as a background disease and 2 patients had coronavirus disease 2019. A fatal outcome was recorded in 4 cases (40% of patients). All the isolates were susceptible to minocycline and levofloxacin. Trimethoprim/sulfamethoxazole and ceftazidime resistance rates were 20% and 40% respectively. Eight different patterns were observed by Pulsed-Field Gel Electrophoresis, only two isolates being clonally identical. The isolation of <i>S. maltophilia</i> in clinical settings requires the implementation of infection prevention measures.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"55 2","pages":"278-282"},"PeriodicalIF":4.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d3/0d/ic-55-278.PMC10323528.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9786517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Post-engraftment Bloodstream Infections After Allogeneic Hematopoietic Cell Transplantation: Risk Factors and Association with Mortality. 同种异体造血细胞移植后血流感染:危险因素及其与死亡率的关系。
IF 4.2 Q2 INFECTIOUS DISEASES Pub Date : 2023-06-01 DOI: 10.3947/ic.2022.0146
Mobil Akhmedov, Galina Klyasova, Larisa Kuzmina, Anastasia Fedorova, Mikhail Drokov, Elena Parovichnikova

Background: Bloodstream infections (BSIs) are major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (allo-HCT). This study aimed to analyze the incidence, etiology, risk factors and outcomes of post-engraftment BSI in allo-HCT recipients.

Materials and methods: The retrospective study included 261 patients with documented engraftment after first allo-HCT performed from January 2018 till September 2021.

Results: Of 261 patients 29 (11.1%) developed at least one post-engraftment BSIs episode with a median time to post-engraftment BSI of 49 days (range, 1 - 158 days from the engraftment). A total of 45 pathogens were isolated from blood - 64.4% (n = 29) were represented by Gram-negative bacteria, and 35.6% (n = 16) - by Gram-positive bacteria. Secondary graft failure (hazard ratio [HR]: 39.93; 95% confidence interval [CI]: 7.64-208.74; P <0.001), secondary poor graft function (HR: 18.07; 95% CI: 3.53 - 92.44; P <0.001), and acute gut graft-versus-host-disease (GvHD) grade II-IV (HR: 29.86; 95% CI: 10.53 - 84.68; P <0.001) were associated with the higher risk of Gram-negative post-engraftment BSIs. Overall 30-day survival after post-engraftment BSIs was 71.4%. By multivariate analysis post-engraftment BSIs (HR: 3.09; 95% CI: 1.29 - 7.38; P = 0.011), and acute gut GvHD grade II-IV (HR: 6.60; 95% CI: 2.78 - 15.68; P <0.001) were associated with the higher 180-day non-relapse mortality risk.

Conclusion: Gram-negative bacteria prevailed in the etiology of post-engraftment BSIs with secondary graft failure. secondary poor graft function. and acute gut GvHD being the main predisposing factors for their development. Post-engraftment BSIs were associated with the higher risk of non-relapse mortality after allo-HCT.

背景:血液感染(bsi)是异基因造血细胞移植(allogeneic hematopoietic cell transplantation, alloo - hct)术后发病和死亡的主要原因。本研究旨在分析同种异体hct受者移植后BSI的发生率、病因、危险因素和结局。材料和方法:回顾性研究包括261例2018年1月至2021年9月首次进行allo-HCT后记录植入的患者。结果:261例患者中,29例(11.1%)出现至少一次植入后BSI发作,植入后BSI的中位时间为49天(从植入后1 - 158天)。共检出45株病原菌,其中革兰氏阴性菌29株,占64.4%,革兰氏阳性菌16株,占35.6%。继发性移植物衰竭(风险比[HR]: 39.93;95%置信区间[CI]: 7.64-208.74;P P P P = 0.011),急性肠道GvHD II-IV级(HR: 6.60;95% ci: 2.78 - 15.68;结论:革兰氏阴性菌在移植后bsi继发移植失败的病因中占主导地位。继发性移植物功能差。急性肠道GvHD是其发展的主要易感因素。植入后脑梗死与同种异体移植后非复发死亡率的高风险相关。
{"title":"Post-engraftment Bloodstream Infections After Allogeneic Hematopoietic Cell Transplantation: Risk Factors and Association with Mortality.","authors":"Mobil Akhmedov,&nbsp;Galina Klyasova,&nbsp;Larisa Kuzmina,&nbsp;Anastasia Fedorova,&nbsp;Mikhail Drokov,&nbsp;Elena Parovichnikova","doi":"10.3947/ic.2022.0146","DOIUrl":"https://doi.org/10.3947/ic.2022.0146","url":null,"abstract":"<p><strong>Background: </strong>Bloodstream infections (BSIs) are major cause of morbidity and mortality after allogeneic hematopoietic cell transplantation (allo-HCT). This study aimed to analyze the incidence, etiology, risk factors and outcomes of post-engraftment BSI in allo-HCT recipients.</p><p><strong>Materials and methods: </strong>The retrospective study included 261 patients with documented engraftment after first allo-HCT performed from January 2018 till September 2021.</p><p><strong>Results: </strong>Of 261 patients 29 (11.1%) developed at least one post-engraftment BSIs episode with a median time to post-engraftment BSI of 49 days (range, 1 - 158 days from the engraftment). A total of 45 pathogens were isolated from blood - 64.4% (n = 29) were represented by Gram-negative bacteria, and 35.6% (n = 16) - by Gram-positive bacteria. Secondary graft failure (hazard ratio [HR]: 39.93; 95% confidence interval [CI]: 7.64-208.74; <i>P</i> <0.001), secondary poor graft function (HR: 18.07; 95% CI: 3.53 - 92.44; <i>P</i> <0.001), and acute gut graft-versus-host-disease (GvHD) grade II-IV (HR: 29.86; 95% CI: 10.53 - 84.68; <i>P</i> <0.001) were associated with the higher risk of Gram-negative post-engraftment BSIs. Overall 30-day survival after post-engraftment BSIs was 71.4%. By multivariate analysis post-engraftment BSIs (HR: 3.09; 95% CI: 1.29 - 7.38; <i>P</i> = 0.011), and acute gut GvHD grade II-IV (HR: 6.60; 95% CI: 2.78 - 15.68; <i>P</i> <0.001) were associated with the higher 180-day non-relapse mortality risk.</p><p><strong>Conclusion: </strong>Gram-negative bacteria prevailed in the etiology of post-engraftment BSIs with secondary graft failure. secondary poor graft function. and acute gut GvHD being the main predisposing factors for their development. Post-engraftment BSIs were associated with the higher risk of non-relapse mortality after allo-HCT.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"55 2","pages":"204-213"},"PeriodicalIF":4.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/32/ef/ic-55-204.PMC10323536.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9790113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Trends in National Pharmaceutical Expenditure in Korea during 2011 - 2020. 2011 - 2020年韩国国家药品支出趋势。
IF 4.2 Q2 INFECTIOUS DISEASES Pub Date : 2023-06-01 DOI: 10.3947/ic.2023.0028
Yujeong Kim, Jungmi Chae, Seohee Shin, Gayoung Jo, Jihye Shin, Byungsoo Kim, Dong-Sook Kim, Jin Yong Lee

Background: This study aimed to identify the trends in pharmaceutical expenditure (PE), share of PE in health expenditure (HE), and trends in expenditure by pharmacological groups (ATC level 1 classification) in Korea for a 10-year period (2011 - 2020) and compare the data with those of other Organisation for Economic Co-operation and Development (OECD) countries. Using the findings, we determined the current status of pharmaceutical expenditure (PE) management in Korea and derived the implications for establishing future macroscopic policies on PE.

Materials and methods: We analyzed the OECD Health Statistics and the Korean national health insurance claims database from January 2011 through December 2020. The outcome measures were HE, PE, and pharmaceutical sales data for ATC level 1 medicines from OECD Health Statistics data during 2011 - 2020. As OECD collects limited ATC level 1 data, we used the HIRA health insurance claims data for PEs of ATC level-1 classification, including D, L, P, and S.

Results: PE in Korea increased by 38.5% from 19.9 billion USD in 2011 to 27.6 billion USD in 2020, whereas the share of PE in HE decreased by 6.3%p from 26.4% in 2011 to 20.1% in 2020. In 2020, Korea ranked third in PE per capita (760.9 USD PPP) and had the highest share of PE (20.1%) among the 19 OECD countries studied. By ATC level 1 class, the highest PE was A (alimentary tract and metabolism) at 4.3 billion USD, and L (antineoplastic and immunomodulating agents) had the highest increase at 13.4%; in contrast, J (anti-infectives for systemic use) had the lowest increase in annual average PE at -0.2% in 2020 relative to 2011. Among the 17 OECD countries, Korea had the highest and the third-highest expenditures for ATC codes A and J, respectively.

Conclusion: PE in Korea has continued to increase between 2011 and 2020, indicating the need for macroscopic management of PE. Our results on PE by ATC code may help health authorities in establishing future policies on PE.

背景:本研究旨在确定韩国10年期间(2011 - 2020年)药品支出(PE)的趋势、PE在卫生支出(HE)中的份额以及药理学组(ATC 1级分类)的支出趋势,并将数据与其他经济合作与发展组织(OECD)国家的数据进行比较。利用这些发现,我们确定了韩国药品支出管理的现状,并得出了制定未来宏观PE政策的意义。材料和方法:从2011年1月到2020年12月,我们分析了经合组织卫生统计和韩国国民健康保险索赔数据库。结果测量是2011 - 2020年OECD卫生统计数据中ATC 1级药物的HE、PE和药品销售数据。由于经合组织收集的ATC一级数据有限,我们使用HIRA健康保险索赔数据对ATC一级分类的PE(包括D、L、P和s)进行了分析。结果:韩国的PE从2011年的199亿美元增加到2020年的276亿美元,增长了38.5%,而PE在HE中的份额从2011年的26.4%下降到2020年的20.1%,下降了6.3%。2020年,韩国的人均PE(760.9美元PPP)排名第三,在经合组织(OECD) 19个国家中占比最高(20.1%)。按ATC 1级分类,PE最高的是A(消化道及代谢),为43亿美元,增幅最高的是L(抗肿瘤及免疫调节剂),增幅为13.4%;相比之下,J(全身使用的抗感染药物)在2020年的年平均PE增幅最低,相对于2011年为-0.2%。在17个经济合作与发展组织(OECD)国家中,韩国的ATC代码A和J的费用分别排在第一位和第三位。结论:2011 - 2020年,韩国PE持续增长,需要对PE进行宏观管理。我们的研究结果可以帮助卫生部门制定未来的体育政策。
{"title":"Trends in National Pharmaceutical Expenditure in Korea during 2011 - 2020.","authors":"Yujeong Kim,&nbsp;Jungmi Chae,&nbsp;Seohee Shin,&nbsp;Gayoung Jo,&nbsp;Jihye Shin,&nbsp;Byungsoo Kim,&nbsp;Dong-Sook Kim,&nbsp;Jin Yong Lee","doi":"10.3947/ic.2023.0028","DOIUrl":"https://doi.org/10.3947/ic.2023.0028","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to identify the trends in pharmaceutical expenditure (PE), share of PE in health expenditure (HE), and trends in expenditure by pharmacological groups (ATC level 1 classification) in Korea for a 10-year period (2011 - 2020) and compare the data with those of other Organisation for Economic Co-operation and Development (OECD) countries. Using the findings, we determined the current status of pharmaceutical expenditure (PE) management in Korea and derived the implications for establishing future macroscopic policies on PE.</p><p><strong>Materials and methods: </strong>We analyzed the OECD Health Statistics and the Korean national health insurance claims database from January 2011 through December 2020. The outcome measures were HE, PE, and pharmaceutical sales data for ATC level 1 medicines from OECD Health Statistics data during 2011 - 2020. As OECD collects limited ATC level 1 data, we used the HIRA health insurance claims data for PEs of ATC level-1 classification, including D, L, P, and S.</p><p><strong>Results: </strong>PE in Korea increased by 38.5% from 19.9 billion USD in 2011 to 27.6 billion USD in 2020, whereas the share of PE in HE decreased by 6.3%p from 26.4% in 2011 to 20.1% in 2020. In 2020, Korea ranked third in PE per capita (760.9 USD PPP) and had the highest share of PE (20.1%) among the 19 OECD countries studied. By ATC level 1 class, the highest PE was A (alimentary tract and metabolism) at 4.3 billion USD, and L (antineoplastic and immunomodulating agents) had the highest increase at 13.4%; in contrast, J (anti-infectives for systemic use) had the lowest increase in annual average PE at -0.2% in 2020 relative to 2011. Among the 17 OECD countries, Korea had the highest and the third-highest expenditures for ATC codes A and J, respectively.</p><p><strong>Conclusion: </strong>PE in Korea has continued to increase between 2011 and 2020, indicating the need for macroscopic management of PE. Our results on PE by ATC code may help health authorities in establishing future policies on PE.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"55 2","pages":"237-246"},"PeriodicalIF":4.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/43/90/ic-55-237.PMC10323532.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10179853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Prevalence and Clinical Significance of Urinary Tract Infection among Neonates Presenting with Unexplained Hyperbilirubinemia in Lebanon: A Retrospective Study. 黎巴嫩不明原因高胆红素血症新生儿尿路感染患病率及临床意义:一项回顾性研究
IF 4.2 Q2 INFECTIOUS DISEASES Pub Date : 2023-06-01 DOI: 10.3947/ic.2022.0117
Alya Harb, Viviane Yassine, Ghassan Ghssein, Ali Salami, Hadi Fakih

Background: Neonatal jaundice is commonly seen in term and preterm newly born babies. It could be either physiologic or secondary to multiple underlying pathologies like urinary tract infection (UTI). Our main objective was to confirm the relationship between neonatal jaundice without apparent cause like hemolysis and the presence of UTI.

Materials and methods: We, retrospectively over a period extended from 2017 to 2020, included 496 babies admitted for elevated indirect hyperbilirubinemia for whom demographic, clinical, laboratory, and therapeutic data were collected through a detailed questionnaire.

Results: Our study included 496 neonates and showed a prevalence of UTI in 8.9% of neonates. The two most common microorganisms in urine culture were Escherichia coli (65.9%) and Klebsiella pneumoniae (25.0%). A multivariate logistic analysis showed that UTI was associated with male neonates (odds ratio [OR] = 2.366, 95% confidence interval [CI]: 1.173 - 4.774; P = 0.016), history of prenatal UTI (OR = 5.378, 95% CI: 2.369 - 12.209; P <0.001), poor feeding (OR = 3.687, 95% CI: 1.570 - 8.661; P = 0.003), and positive urine culture in catheter (OR = 2.704, 95% CI: 1.255 - 5.826; P = 0.011). The mean length of stay was higher in patients with positive UTI (Median = 216 hours) compared to patients with negative UTI (Median = 48 hours) (P <0.001).

Conclusion: Neonatal sreening for UTI should be recommended whenever there is unexplaind early or prolonged hyperbilirubinemia with no evidence of alloimmune hemolysis or blood group incompatibility and to prevent the morbidity of urosepsis and congenital kidneys malformations.

背景:新生儿黄疸常见于足月及早产新生儿。它可能是生理性的,也可能是继发于多种潜在病理,如尿路感染(UTI)。我们的主要目的是确认没有明显原因的新生儿黄疸如溶血和尿路感染的存在之间的关系。材料和方法:我们回顾性分析了2017年至2020年期间因间接高胆红素血症升高而入院的496名婴儿,通过详细的问卷调查收集了他们的人口统计学、临床、实验室和治疗数据。结果:我们的研究纳入了496名新生儿,显示8.9%的新生儿存在尿路感染。尿液培养中最常见的两种微生物是大肠杆菌(65.9%)和肺炎克雷伯菌(25.0%)。多因素logistic分析显示UTI与男性新生儿相关(优势比[OR] = 2.366, 95%可信区间[CI]: 1.173 - 4.774;P = 0.016),产前尿路感染史(OR = 5.378, 95% CI: 2.369 ~ 12.209;P = 0.003),尿管培养阳性(OR = 2.704, 95% CI: 1.255 ~ 5.826;P = 0.011)。尿路感染阳性患者的平均住院时间(中位数= 216小时)高于尿路感染阴性患者(中位数= 48小时)(P结论:在没有同种免疫溶血或血型不相容证据的情况下,如果出现不明原因的早期或长期高胆红素血症,应推荐新生儿进行尿路感染筛查,以预防尿脓毒症和先天性肾脏畸形的发生。
{"title":"Prevalence and Clinical Significance of Urinary Tract Infection among Neonates Presenting with Unexplained Hyperbilirubinemia in Lebanon: A Retrospective Study.","authors":"Alya Harb,&nbsp;Viviane Yassine,&nbsp;Ghassan Ghssein,&nbsp;Ali Salami,&nbsp;Hadi Fakih","doi":"10.3947/ic.2022.0117","DOIUrl":"https://doi.org/10.3947/ic.2022.0117","url":null,"abstract":"<p><strong>Background: </strong>Neonatal jaundice is commonly seen in term and preterm newly born babies. It could be either physiologic or secondary to multiple underlying pathologies like urinary tract infection (UTI). Our main objective was to confirm the relationship between neonatal jaundice without apparent cause like hemolysis and the presence of UTI.</p><p><strong>Materials and methods: </strong>We, retrospectively over a period extended from 2017 to 2020, included 496 babies admitted for elevated indirect hyperbilirubinemia for whom demographic, clinical, laboratory, and therapeutic data were collected through a detailed questionnaire.</p><p><strong>Results: </strong>Our study included 496 neonates and showed a prevalence of UTI in 8.9% of neonates. The two most common microorganisms in urine culture were <i>Escherichia coli</i> (65.9%) and <i>Klebsiella pneumoniae</i> (25.0%). A multivariate logistic analysis showed that UTI was associated with male neonates (odds ratio [OR] = 2.366, 95% confidence interval [CI]: 1.173 - 4.774; <i>P</i> = 0.016), history of prenatal UTI (OR = 5.378, 95% CI: 2.369 - 12.209; <i>P</i> <0.001), poor feeding (OR = 3.687, 95% CI: 1.570 - 8.661; <i>P</i> = 0.003), and positive urine culture in catheter (OR = 2.704, 95% CI: 1.255 - 5.826; <i>P</i> = 0.011). The mean length of stay was higher in patients with positive UTI (Median = 216 hours) compared to patients with negative UTI (Median = 48 hours) (<i>P</i> <0.001).</p><p><strong>Conclusion: </strong>Neonatal sreening for UTI should be recommended whenever there is unexplaind early or prolonged hyperbilirubinemia with no evidence of alloimmune hemolysis or blood group incompatibility and to prevent the morbidity of urosepsis and congenital kidneys malformations.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"55 2","pages":"194-203"},"PeriodicalIF":4.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/9f/74/ic-55-194.PMC10323526.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10161088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
Antibiotic Combination Therapy for Severe Scrub Typhus: Is It Necessary? 抗生素联合治疗严重恙虫病是否必要?
IF 4.2 Q2 INFECTIOUS DISEASES Pub Date : 2023-06-01 DOI: 10.3947/ic.2023.0055
Moon-Hyun Chung, Jin-Soo Lee, Jae Hyoung Im

Scrub typhus can be adequately treated with doxycycline or azithromycin unless it is treated too late. Such cases present as severe scrub typhus, and their treatment remains a challenging problem. In this article, we briefly review the literature on the treatment of scrub typhus and the limitations of the combination of doxycycline and azithromycin. Several options are suggested for further study in the treatment of severe scrub typhus (such as encephalitis, myocarditis, and pneumonia), including dose escalation of doxycycline, the adjuvant use of steroids, the selective use of beta-lactam antibiotics, and the use of tigecycline.

除非治疗太晚,否则可以用强力霉素或阿奇霉素对恙虫病进行充分治疗。这些病例表现为严重的恙虫病,其治疗仍然是一个具有挑战性的问题。本文就多西环素与阿奇霉素联用治疗恙虫病的文献作一综述。建议进一步研究治疗严重恙虫病(如脑炎、心肌炎和肺炎)的几种选择,包括增加强力霉素的剂量、辅助使用类固醇、选择性使用β -内酰胺类抗生素和使用替加环素。
{"title":"Antibiotic Combination Therapy for Severe Scrub Typhus: Is It Necessary?","authors":"Moon-Hyun Chung,&nbsp;Jin-Soo Lee,&nbsp;Jae Hyoung Im","doi":"10.3947/ic.2023.0055","DOIUrl":"https://doi.org/10.3947/ic.2023.0055","url":null,"abstract":"<p><p>Scrub typhus can be adequately treated with doxycycline or azithromycin unless it is treated too late. Such cases present as severe scrub typhus, and their treatment remains a challenging problem. In this article, we briefly review the literature on the treatment of scrub typhus and the limitations of the combination of doxycycline and azithromycin. Several options are suggested for further study in the treatment of severe scrub typhus (such as encephalitis, myocarditis, and pneumonia), including dose escalation of doxycycline, the adjuvant use of steroids, the selective use of beta-lactam antibiotics, and the use of tigecycline.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"55 2","pages":"179-184"},"PeriodicalIF":4.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/cb/2c/ic-55-179.PMC10323529.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10161087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Clinical Features and Outcomes of Invasive Fusariosis: A Case Series in a Single Center with Literature Review. 侵袭性镰孢病的临床特征和预后:单中心病例系列并文献回顾。
IF 4.2 Q2 INFECTIOUS DISEASES Pub Date : 2023-06-01 DOI: 10.3947/ic.2018.0717
Ji Yeon Kim, Cheol In Kang, Ji Hye Lee, Woo Joo Lee, Kyungmin Huh, Sun Young Cho, Doo Ryeon Chung, Kyong Ran Peck

Fusarium species, which are commonly found in soil, water, and organic substrates, can cause serious infections especially in immunocompromised patients. Fusarium infection is notoriously difficult to treat, because of their inherently high minimum inhibitory concentrations (MICs) to most antifungal agents. There have been limited data on invasive fusariosis in Korea. We identified 57 patients with culture-proven fusariosis at Samsung Medical Center, Seoul, Korea, from September 2003 through January 2017. Invasive fusariosis was defined as any case with at least one positive blood culture or with concurrent involvement of 2 or more non-contiguous sites. Superficial infections such as keratitis and onychomycosis were excluded. We reported 14 cases of invasive fusariosis categorized according to the European Organization for Research and Treatment of Cancer/Mycoses Study Group criteria, of which 6 cases were fusarium fungemia. Hematologic malignancies (7/14, 50%), solid organ transplantation (2/14, 14.2%), or immunosuppressive therapy (2/14, 14.2%), were the predominant underlying conditions. The overall mortality rate was 37%, however, that of disseminated fusariosis was up to 83%. Antifungal treatment with voriconazole or liposomal amphotericin B was commonly administered. In this report, we described the clinical characteristics and treatment outcomes of invasive fusariosis in Korea. Given the high mortality in disseminated cases, invasive fusariosis is becoming a therapeutic challenge to clinicians treating immunocompromised patients.

镰刀菌常见于土壤、水和有机基质中,可引起严重感染,特别是在免疫功能低下的患者中。众所周知,镰孢菌感染很难治疗,因为它们对大多数抗真菌药物具有固有的高最低抑制浓度(mic)。韩国关于侵袭性镰孢病的数据有限。从2003年9月到2017年1月,我们在韩国首尔的三星医疗中心发现了57例经培养证实的镰孢菌病患者。侵袭性镰孢病定义为至少有一个血培养阳性或同时累及2个或更多不相邻部位的任何病例。排除角膜炎、甲癣等浅表感染。根据欧洲癌症研究和治疗组织/真菌病研究组的标准,我们报告了14例侵袭性镰孢菌病,其中6例为镰孢菌血症。血液系统恶性肿瘤(7/ 14,50 %)、实体器官移植(2/ 14,14 %)或免疫抑制治疗(2/ 14,14 %)是主要的基础条件。总死亡率为37%,但播散性镰孢病的死亡率高达83%。常用伏立康唑或两性霉素B脂质体进行抗真菌治疗。在本报告中,我们描述了韩国侵袭性镰孢病的临床特征和治疗结果。鉴于播散性病例的高死亡率,侵袭性镰孢病正在成为临床医生治疗免疫功能低下患者的治疗挑战。
{"title":"Clinical Features and Outcomes of Invasive Fusariosis: A Case Series in a Single Center with Literature Review.","authors":"Ji Yeon Kim,&nbsp;Cheol In Kang,&nbsp;Ji Hye Lee,&nbsp;Woo Joo Lee,&nbsp;Kyungmin Huh,&nbsp;Sun Young Cho,&nbsp;Doo Ryeon Chung,&nbsp;Kyong Ran Peck","doi":"10.3947/ic.2018.0717","DOIUrl":"https://doi.org/10.3947/ic.2018.0717","url":null,"abstract":"<p><p><i>Fusarium</i> species, which are commonly found in soil, water, and organic substrates, can cause serious infections especially in immunocompromised patients. Fusarium infection is notoriously difficult to treat, because of their inherently high minimum inhibitory concentrations (MICs) to most antifungal agents. There have been limited data on invasive fusariosis in Korea. We identified 57 patients with culture-proven fusariosis at Samsung Medical Center, Seoul, Korea, from September 2003 through January 2017. Invasive fusariosis was defined as any case with at least one positive blood culture or with concurrent involvement of 2 or more non-contiguous sites. Superficial infections such as keratitis and onychomycosis were excluded. We reported 14 cases of invasive fusariosis categorized according to the European Organization for Research and Treatment of Cancer/Mycoses Study Group criteria, of which 6 cases were fusarium fungemia. Hematologic malignancies (7/14, 50%), solid organ transplantation (2/14, 14.2%), or immunosuppressive therapy (2/14, 14.2%), were the predominant underlying conditions. The overall mortality rate was 37%, however, that of disseminated fusariosis was up to 83%. Antifungal treatment with voriconazole or liposomal amphotericin B was commonly administered. In this report, we described the clinical characteristics and treatment outcomes of invasive fusariosis in Korea. Given the high mortality in disseminated cases, invasive fusariosis is becoming a therapeutic challenge to clinicians treating immunocompromised patients.</p>","PeriodicalId":51616,"journal":{"name":"Infection and Chemotherapy","volume":"55 2","pages":"290-294"},"PeriodicalIF":4.2,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/3d/ae/ic-55-290.PMC10323523.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9783955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 5
期刊
Infection and Chemotherapy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1